Merkel Cell Carcinoma clinical trials at UCSF
3 in progress, 2 open to eligible people
Merkel cell carcinoma is a skin cancer that's not common. UCSF is studying a drug to see if it's safe and if it can make tumors smaller. UCSF is also studying how well a drug named RP1 works in people who had organ transplants and now have serious skin cancers.
Beta-only IL-2 ImmunoTherapY Study
open to eligible people ages 18 years and up
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
San Francisco, California and other locations
RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies
open to eligible people ages 18 years and up
This Phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients. This will include patients with either previous renal, hepatic, heart, lung, or other solid organ transplantation or hematopoietic cell transplant and experiencing subsequent documented locally advanced or metastatic cutaneous malignancies. The study will enroll a total of 65 evaluable patients. Patients will participate up to approximately 3 years including a 28-day screening period, up to approximately 1 year treatment period, and a 2-year follow-up period.
San Francisco, California and other locations
INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
Sorry, in progress, not accepting new patients
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).
San Francisco, California and other locations
Our lead scientists for Merkel Cell Carcinoma research studies include Katy Tsai, MD.
Last updated: